|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5620 EUR | +9.98% |
|
0.00% | -63.28% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 46.55M | - | - | - | - | |
| 324B | |||||
| 68.88B | |||||
| 9.72B | |||||
| 8.37B | |||||
| 4.32B |
- Stock Market
- Stocks
- AB Stock
- Charts AB Science
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
